Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

Rosales, Raymond and Balcaitiene, Jovita and Berard, Hugues and Maisonobe, Pascal and Goh, Khean and Kumthornthip, Witsanu and Mazlan, Mazlina and Abdul Latif, Lydia and Delos Santos, Mary and Chotiyarnwong, Chayaporn and Tanvijit, Phakamas and Nuez, Odessa and Kong, Keng (2018) Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins, 10 (7). p. 253. ISSN 2072-6651, DOI https://doi.org/10.3390/toxins10070253.

Full text not available from this repository.
Official URL: https://doi.org/10.3390/toxins10070253


The ONTIME study investigated whether early post-stroke abobotulinumtoxinA injection delays appearance or progression of upper limb spasticity (ULS) symptoms. ONTIME (NCT02321436) was a 28-week, exploratory, double-blind, randomized, placebo-controlled study of abobotulinumtoxinA 500U in patients with ULS (Modified Ashworth Scale [MAS] score ≥ 2) 2–12 weeks post-stroke. Patients were either symptomatic or asymptomatic (only increased MAS) at baseline. Primary efficacy outcome measure: time between injection and visit at which re-injection criteria were met (MAS ≥ 2 and ≥1, sign of symptomatic spasticity: pain, involuntary movements, impaired active or passive function). Forty-two patients were randomized (abobotulinumtoxinA 500U: n = 28; placebo: n = 14) with median 5.86 weeks since stroke. Median time to reach re-injection criteria was significantly longer for abobotulinumtoxinA (156 days) than placebo (32 days; log-rank: p = 0.0176; Wilcoxon: p = 0.0480). Eleven (39.3%) patients receiving abobotulinumtoxinA did not require re-injection for ≥28 weeks versus two (14.3%) in placebo group. In this exploratory study, early abobotulinumtoxinA treatment significantly delayed time to reach re-injection criteria compared with placebo in patients with post-stroke ULS. These findings suggest an optimal time for post-stroke spasticity management and help determine the design and sample sizes for larger confirmatory studies.

Item Type: Article
Funders: Ipsen Pharma
Uncontrolled Keywords: abobotulinumtoxinA; botulinum toxin type A; upper limb spasticity; post-stroke; early use; ONTIME
Subjects: R Medicine
Divisions: Faculty of Medicine
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 10 Apr 2019 04:35
Last Modified: 25 May 2021 03:17
URI: http://eprints.um.edu.my/id/eprint/20873

Actions (login required)

View Item View Item